Thus, anti-CD3/CD28 antibody activation and signaling through T cells augments the percentages of CD8+ T cells moderately, and the levels of expansion are less by cancer patients’ CD8+ T cells when compared to CD8+ T cells expanded from healthy individuals (Fig. 3D,E). This evidence concerns the gene CD8A and cancer.